Attallah A M, Omran D, Marie M S, Abdelrazek Mohamed, Salama A, El Essawey R, Mobarak L, Maklad S, Omar A
a Research & Development Department , Biotechnology Research Center , New Damietta , Egypt.
b Department of Endemic Medicine and Hepatology, Faculty of Medicine , Cairo University , Cairo , Egypt.
Br J Biomed Sci. 2018 Oct;75(4):157-162. doi: 10.1080/09674845.2018.1489599. Epub 2018 Aug 21.
A single nucleotide polymorphism (SNP) in the interleukin 28B (IL28B) gene may alter the trajectory of hepatitis C virus (HCV) chronic infection. Several studies have sought to determine a link between IL28B rs12979860 SNP and the development of HCV-related hepatocellular carcinoma (HCC), but with variable results, and consensus is awaited. We hypothesised that IL28B rs12979860 SNP is linked to HCC in patients with HCV type 4.
IL28B genotyping of 300 patients with HCV-related fibrosis (n = 100), cirrhosis (n = 100) and HCC (n = 100) was carried out and the results were analysed to determine the association between the IL28B genotype and clinical outcome.
In IL28B TT genotype carriers, the proportions of moderate/severe fibrosis, advanced cirrhosis (Child B-C) and HCC (50%, 84% and 60.2%, respectively) were higher (p < 0.05) than in CC/CT (4.3%, 46% and 23%, respectively). IL-28B SNP was linked significantly (p < 0.05) with cirrhosis progression and HCC advanced stages. Moreover, HCC advanced Child, Okuda and CLIP stages were associated with T allele carriage (73.9%, 82.6% and 78.3% vs. 44.2%, 50.6% and 46.8% in CC/CT). The percentage of large tumour size (> 3cm) increased (p = 0.028) in TT genotype carriers (81.8% vs.52.6% in CC/CT).
IL-28B rs12979860 TT genotype is more prevalent in patients with advanced fibrosis, cirrhosis and HCC stages. Thus, it seems to be associated with poor outcomes in chronic HCV patients and to augment the risk of developing HCC.
白细胞介素28B（IL28B）基因中的单核苷酸多态性（SNP）可能会改变丙型肝炎病毒（HCV）慢性感染的病程。多项研究试图确定IL28B rs12979860 SNP与HCV相关肝细胞癌（HCC）发生之间的联系，但结果不一，仍有待达成共识。我们推测IL28B rs12979860 SNP与4型HCV患者的HCC有关。
对300例HCV相关纤维化患者（n = 100）、肝硬化患者（n = 100）和HCC患者（n = 100）进行IL28B基因分型，并分析结果以确定IL28B基因型与临床结局之间的关联。
在IL28B TT基因型携带者中，中度/重度纤维化、晚期肝硬化（Child B - C级）和HCC的比例（分别为50%、84%和60.2%）高于CC/CT基因型携带者（分别为4.3%、46%和23%）（p < 0.05）。IL - 28B SNP与肝硬化进展和HCC晚期显著相关（p < 0.05）。此外，HCC晚期的Child、Okuda和CLIP分期与T等位基因携带有关（分别为73.9%、82.6%和78.3%，而CC/CT基因型携带者为44.2%、50.6%和46.8%）。TT基因型携带者中大肿瘤大小（> 3cm）的比例增加（p = 0.028）（81.8% vs. CC/CT基因型携带者的52.6%）。
IL - 28B rs12979860 TT基因型在晚期纤维化、肝硬化和HCC分期患者中更为普遍。因此，它似乎与慢性HCV患者的不良结局相关，并增加了发生HCC的风险。
